Analysts: These Healthcare Stocks Could Soar 50%

ALDR and DCPH stocks both scored new 'buy' ratings and lofty price targets

Aug 7, 2018 at 1:51 PM
facebook twitter linkedin

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) will step into the earnings confessional after the close today. Ahead of the event, analysts at Stifel launched coverage with a "buy" rating and a $30 price target -- a premium of more than 50% to Monday's close at $19.20. Likewise, sector peer Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) also scored a new "buy" rating, with Canaccord Genuity issuing a price target of $55 -- again, more than 50% above yesterday's close of $35.96.

Short Squeeze Could Push ALDR Stock Above Round-Number Resistance

Alder Biopharmaceuticals stock touched an annual high of $20 today, but has since pulled back 0.3% to trade at $19.15. The round-number $20 level previously acted as support for ALDR shares in early 2017, before switching to resistance. It's also home to a trendline connecting the stock's higher highs since January. Since the security's March lows -- stemming from an abrupt CEO departure -- Alder stock has surged 76%.

ALDR stock chart august 7

The shares jumped 5% the day after the company's May earnings report, and another strong earnings showing -- or a well-received presentation at Canaccord's healthcare conference later this week -- could spook some shorts. Short interest represents more than 20% of ALDR's total available float, and would take more than 12 sessions to buy back, at the stock's average pace of trading -- plenty of fuel for a potential short squeeze.

DCPH Stock Bounces from Key Level

Deciphera Pharmaceuticals stock is up 0.5% at $37.23, thanks to the new Canaccord rating and price target. The analyst waxed optimistic on the company's lead drug candidate, DCC-2618 -- data which sent DCPH shares soaring in early June. The company is also expected to present at the Canaccord Genuity Growth Conference this week.

Since peaking at an all-time high of $45.61 on June 18, DCPH stock has pulled back 18%. However, the stock found support in the $34 region, which is double its September 2017 initial public offering (IPO) price of $17, and represents a 59% gain year-to-date.

DCPH stock chart august 7

However, the healthcare stock is no stranger to upbeat analyst attention. In fact, seven of eight analysts already consider DCPH a "buy" or better, with the other doling out a lukewarm "hold" rating. In the same vein, the consensus 12-month price target of $56.43 represents expected upside of 51.5% to the equity's current perch, and stands in uncharted territory.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners